Correction: Zealand Pharma – Transactions related to share buy-back program (week 35, 2026)
Company announcement No. 45 / 2026
Correction: Zealand Pharma – Transactions related to share buy-back program (week 35, 2026)
Copenhagen, Denmark, September 2, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, hereby corrects information regarding the dates for the reported transactions related to its share buy-back program (the “Program”) for week 35 (August 24 – August 28, 2026), initially published in company announcement no. 44 / 2026 on August 31, 2026, as the correct dates for week 35 have now been added to the report on transactions for this period in the reporting table. No other information in the company announcement is affected by this correction, and there has been no change to the annex contained in the original company announcement, which has been reattached to this correction. The complete corrected company announcement is set out below.
Correction to company announcement No. 44/2026 – Full corrected version:
Copenhagen, Denmark, August 31, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 35 (August 24 – August 28, 2026).
The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”). Reference is made to company announcement no. 15 / 2026 dated May 7, 2026, which sets out the full terms of the Program. Under the Program, Zealand Pharma may repurchase shares for a total consideration of up to DKK 1.3 billion. The maximum number of shares that may be acquired under the Program is 7,152,557, and the Program commenced on May 7, 2026, and will be completed no later than October 31, 2026. The Company has appointed Danske Bank as lead manager for the Program. Danske Bank will make its own trading decisions independently of, and without influence from, the Company.
Transactions executed in week 35
The following transactions have been executed on Nasdaq Copenhagen (XCSE) under the Program during week 35 (August 24, 2026 – August 28, 2026):
|
Date |
Number of shares |
Average purchase price (DKK) |
Transaction value (DKK) |
|
Accumulated as per latest announcement |
2,727,000 |
825,199,570 |
|
|
24/08/2026 |
27,000 |
313.73 |
8,470,710 |
|
25/08/2026 |
25,000 |
325.16 |
8,129,000 |
|
26/08/2026 |
28,000 |
320.52 |
8,974,560 |
|
27/08/2026 |
28,000 |
318.52 |
8,918,560 |
|
28/08/2026 |
28,000 |
318.26 |
8,911,280 |
|
Accumulated (W35) |
136,000 |
|
43,404,110 |
|
Total accumulated |
2,863,000 |
|
868,603,680 |
